2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence function
2020
Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers
Fan D, Kang JJ, Fan M, Wang H, Lee A, Yu Y, Chen L, Tsai C, McBride SM, Riaz N, Gelblum DY, Neal BP, Fetten J, Dunn LA, Michel LS, Boyle JO, Cohen MA, Roman BR, Ganly I, Singh B, Wong RJ, Sherman EJ, Lee NY. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology 2020, 104: 104641. PMID: 32182548, PMCID: PMC8480112, DOI: 10.1016/j.oraloncology.2020.104641.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalQuad Shot regimenOverall survivalPalliative responseRadiation therapyNeck cancerMedian locoregional progression-free survivalGrade 3 toxicity ratesOverall palliative response rateMedian overall survivalPalliative response ratePrior radiation therapyProgression-free survivalRadiation-related toxicityFree survivalPalliative therapyMedian ageLocal therapyPalliative optionSurvival improvementProton radiation therapyToxicity ratesTumor reductionIrradiated headLocal treatment
2019
A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.
Tchekmedyian V, Ho A, Dunn L, Fetten J, Pfister D, Lobaugh S, Zhang Z, Kang J, Chen L, Riaz N, McBride S, Yu Y, Tsai C, Lee N, Sherman E. A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2019, 37: 6079-6079. DOI: 10.1200/jco.2019.37.15_suppl.6079.Peer-Reviewed Original ResearchHPV/p16 statusOverall survivalRetrospective analysisTotal doseT stageP16 statusMultivariate Cox proportional hazards modelMultivariate analysisMedian f/uCox proportional hazards regressionCox proportional hazards modelNeck squamous cell carcinomaHPV/p16Start of RTProportional hazards regressionSquamous cell carcinomaSplit-dose administrationProportional hazards modelCI dosingPrimary CRTInduction chemotherapyCRT outcomesDistant failureProspective trialMedian age